000045558 001__ 45558
000045558 005__ 20200402205932.0
000045558 0247_ $$2WOS$$aWOS:000231962300011
000045558 037__ $$aPreJuSER-45558
000045558 041__ $$aeng
000045558 082__ $$a610
000045558 084__ $$2WoS$$aInfectious Diseases
000045558 084__ $$2WoS$$aPharmacology & Pharmacy
000045558 084__ $$2WoS$$aVirology
000045558 1001_ $$0P:(DE-HGF)0$$aHarrer, E.$$b0
000045558 245__ $$aTherapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption
000045558 260__ $$aLondon$$bInternational Medical Press$$c2005
000045558 300__ $$a285 - 300
000045558 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000045558 3367_ $$2DataCite$$aOutput Types/Journal article
000045558 3367_ $$00$$2EndNote$$aJournal Article
000045558 3367_ $$2BibTeX$$aARTICLE
000045558 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000045558 3367_ $$2DRIVER$$aarticle
000045558 440_0 $$013902$$aAntiviral Therapy$$v10$$x1359-6535
000045558 500__ $$aRecord converted from VDB: 12.11.2012
000045558 520__ $$aThe safety and immunogenicity of an HIV-1 nef-expressing modified vaccinia virus Ankara (MVA) was investigated in 14 HIV-1-positive patients (CD4 > 400/mu l) on highly active antiretroviral therapy (HAART). Patients were vaccinated at weeks 0, 4 and 16, followed by interruption of HAART at week 18. MVA-nef was well tolerated except for local reactions, with only mild systemic side effects reported in a few patients. Vaccination with MVA-nef was associated with recognition of new HIV-1 T-cell epitopes (cytotoxic T-lymphocyte epitopes in 9/14 patients, CD4 epitope/recombinant Nef protein in 2/14) and an increase in CD4+ and CD8+ T cells. All patients had been vaccinated against smallpox and a strong T-cell and antibody response to MVA was induced in all patients. After interruption of HAART, viral load rebounded in all patients, but after a median time of 36 (4-76) weeks in 9/14 patients, viraemia remained below the pre-HAART viral load and CD4 counts stayed above the pre-HAART levels. While six patients have remained off therapy for a median time of 64 (57-76) weeks, HAART was resumed in 8/14 patients after a median treatment interruption time of 15 (4-38) weeks. This study has demonstrated that MVA-nef is safe and immunogenic in HIV-1-infected subjects and has provided encouraging data on the potential of therapeutic vaccinations.
000045558 536__ $$0G:(DE-Juel1)FUEK255$$2G:(DE-HGF)$$aNeurowissenschaften$$cL01$$x0
000045558 588__ $$aDataset connected to Web of Science
000045558 650_7 $$2WoSType$$aJ
000045558 7001_ $$0P:(DE-HGF)0$$aBäuerle, M.$$b1
000045558 7001_ $$0P:(DE-HGF)0$$aFerstl, B.$$b2
000045558 7001_ $$0P:(DE-HGF)0$$aChaplin, I. T.$$b3
000045558 7001_ $$0P:(DE-HGF)0$$aPetzold, B.$$b4
000045558 7001_ $$0P:(DE-HGF)0$$aMateo, L.$$b5
000045558 7001_ $$0P:(DE-HGF)0$$aHandley, A.$$b6
000045558 7001_ $$0P:(DE-HGF)0$$aTzatzaris, M.$$b7
000045558 7001_ $$0P:(DE-HGF)0$$aVollmar, J.$$b8
000045558 7001_ $$0P:(DE-HGF)0$$aBermann, S.$$b9
000045558 7001_ $$0P:(DE-HGF)0$$aRittmaier, M.$$b10
000045558 7001_ $$0P:(DE-HGF)0$$aEismann, K.$$b11
000045558 7001_ $$0P:(DE-HGF)0$$aMiller, S.$$b12
000045558 7001_ $$0P:(DE-HGF)0$$aKalden, J. R.$$b13
000045558 7001_ $$0P:(DE-HGF)0$$aSpriewald, B.$$b14
000045558 7001_ $$0P:(DE-Juel1)132029$$aWillbold, D.$$b15$$uFZJ
000045558 7001_ $$0P:(DE-HGF)0$$aHarrer, T.$$b16
000045558 773__ $$0PERI:(DE-600)2118396-X$$gVol. 10, p. 285 - 300$$p285 - 300$$q10<285 - 300$$tAntiviral therapy$$v10$$x1359-6535$$y2005
000045558 909CO $$ooai:juser.fz-juelich.de:45558$$pVDB
000045558 9131_ $$0G:(DE-Juel1)FUEK255$$bLeben$$kL01$$lFunktion und Dysfunktion des Nervensystems$$vNeurowissenschaften$$x0
000045558 9141_ $$y2005
000045558 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000045558 9201_ $$0I:(DE-Juel1)VDB58$$d31.12.2006$$gIBI$$kIBI-2$$lBiologische Strukturforschung$$x0
000045558 970__ $$aVDB:(DE-Juel1)69727
000045558 980__ $$aVDB
000045558 980__ $$aConvertedRecord
000045558 980__ $$ajournal
000045558 980__ $$aI:(DE-Juel1)ISB-2-20090406
000045558 980__ $$aUNRESTRICTED
000045558 980__ $$aI:(DE-Juel1)ICS-6-20110106
000045558 981__ $$aI:(DE-Juel1)IBI-7-20200312
000045558 981__ $$aI:(DE-Juel1)ISB-2-20090406
000045558 981__ $$aI:(DE-Juel1)ICS-6-20110106